» Articles » PMID: 35563060

Role of Glycogen Synthase Kinase-3 in Interferon-γ-Mediated Immune Hepatitis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 May 14
PMID 35563060
Authors
Affiliations
Soon will be listed here.
Abstract

Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is a vital glycogen synthase regulator controlling glycogen synthesis, glucose metabolism, and insulin signaling. GSK-3 is widely expressed in different types of cells, and its abundant roles in cellular bioregulation have been speculated. Abnormal GSK-3 activation and inactivation may affect its original bioactivity. Moreover, active and inactive GSK-3 can regulate several cytosolic factors and modulate their diverse cellular functional roles. Studies in experimental liver disease models have illustrated the possible pathological role of GSK-3 in facilitating acute hepatic injury. Pharmacologically targeting GSK-3 is therefore suggested as a therapeutic strategy for liver protection. Furthermore, while the signaling transduction of GSK-3 facilitates proinflammatory interferon (IFN)-γ in vitro and in vivo, the blockade of GSK-3 can be protective, as shown by an IFN-γ-induced immune hepatitis model. In this study, we explored the possible regulation of GSK-3 and the potential relevance of GSK-3 blockade in IFN-γ-mediated immune hepatitis.

Citing Articles

Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.

Demir T, Moloney C, Mahalingam D Cancers (Basel). 2025; 17(5).

PMID: 40075563 PMC: 11898821. DOI: 10.3390/cancers17050715.


Targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells.

Markovska A, Somers K, Guillaume J, Melief J, Mazar A, Schmitt D Sci Rep. 2024; 14(1):21710.

PMID: 39289439 PMC: 11408500. DOI: 10.1038/s41598-024-72492-y.


PECAM-1 drives β-catenin-mediated EndMT via internalization in colon cancer with diabetes mellitus.

Wu Q, Du X, Cheng J, Qi X, Liu H, Lv X Cell Commun Signal. 2023; 21(1):203.

PMID: 37580771 PMC: 10426208. DOI: 10.1186/s12964-023-01193-2.

References
1.
Rocha J, Figueira M, Barateiro A, Fernandes A, Brites D, Pinto R . Inhibition of glycogen synthase kinase-3β attenuates organ injury and dysfunction associated with liver ischemia-reperfusion and thermal injury in the rat. Shock. 2014; 43(4):369-78. DOI: 10.1097/SHK.0000000000000298. View

2.
Takaoka A, Tanaka N, Mitani Y, Miyazaki T, Fujii H, Sato M . Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling. EMBO J. 1999; 18(9):2480-8. PMC: 1171330. DOI: 10.1093/emboj/18.9.2480. View

3.
MIZUHARA H, ONeill E, Seki N, Ogawa T, Kusunoki C, Otsuka K . T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med. 1994; 179(5):1529-37. PMC: 2191474. DOI: 10.1084/jem.179.5.1529. View

4.
Hoeflich K, Luo J, Rubie E, Tsao M, Jin O, Woodgett J . Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000; 406(6791):86-90. DOI: 10.1038/35017574. View

5.
Cohen P, Frame S . The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001; 2(10):769-76. DOI: 10.1038/35096075. View